{"id":"https://openalex.org/W2892083382","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.8021","title":"Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).","display_name":"Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).","publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2892083382","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.8021","mag":"2892083382"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.8021","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.8021","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.8021","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057911528","display_name":"Andrzej J. Jakubowiak","orcid":"https://orcid.org/0000-0002-2597-6822","observed_orcids":["https://orcid.org/0000-0002-2597-6822"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrzej J. Jakubowiak","raw_affiliation_strings":["University of Chicago Medical Center, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Medical Center, Chicago, IL;","institution_ids":["https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000218289","display_name":"\u00c1gnes Benedict","orcid":"https://orcid.org/0000-0002-4747-4575","observed_orcids":["https://orcid.org/0000-0002-4747-4575"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Agnes Benedict","raw_affiliation_strings":["Evidera Inc., Budapest, Hungary;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera Inc., Budapest, Hungary;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087574931","display_name":"Sumeet S. Panjabi","orcid":"https://orcid.org/0000-0002-5093-8510","observed_orcids":["https://orcid.org/0000-0002-5093-8510"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumeet Panjabi","raw_affiliation_strings":["Amgen Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055349619","display_name":"Ivan Houisse","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivan Houisse","raw_affiliation_strings":["Evidera Inc., Budapest, Hungary;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera Inc., Budapest, Hungary;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108673058","display_name":"Marco Campioni","orcid":"https://orcid.org/0000-0002-4373-1669","observed_orcids":["https://orcid.org/0000-0002-4373-1669"]},"institutions":[{"id":"https://openalex.org/I4210139000","display_name":"Amgen (Switzerland)","ror":"https://ror.org/045wjte67","country_code":"CH","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210139000"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Marco Campioni","raw_affiliation_strings":["Amgen Inc., Zug, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Zug, Switzerland;","institution_ids":["https://openalex.org/I4210139000"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003244323","display_name":"Andromachi Giannopoulou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139000","display_name":"Amgen (Switzerland)","ror":"https://ror.org/045wjte67","country_code":"CH","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210139000"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Andromachi Giannopoulou","raw_affiliation_strings":["Amgen Inc., Zug, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Zug, Switzerland;","institution_ids":["https://openalex.org/I4210139000"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112233910","display_name":"Sanjay Kumar Aggarwal","orcid":"https://orcid.org/0009-0009-9156-7910","observed_orcids":["https://orcid.org/0009-0009-9156-7910"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay Aggarwal","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003015868","display_name":"Rafa\u00ebl Fonseca","orcid":"https://orcid.org/0000-0002-5938-3769","observed_orcids":["https://orcid.org/0000-0002-5938-3769"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rafael Fonseca","raw_affiliation_strings":["Mayo Clinic, Scottsdale, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Scottsdale, AZ;","institution_ids":["https://openalex.org/I4210125099"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"8021","last_page":"8021"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.5059000253677368,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.5059000253677368,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.4844000041484833,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":0.9120000004768372},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9919999837875366},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9980000257492065},{"id":"https://openalex.org/keywords/krd","display_name":"KRd","score":0.7049999833106995},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9860000014305115},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8690000176429749},{"id":"https://openalex.org/keywords/aspire-trial","display_name":"ASPIRE trial","score":0.7160000205039978},{"id":"https://openalex.org/keywords/post-progression-survival","display_name":"post-progression survival","score":0.6549999713897705},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4690000116825104},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.5479999780654907},{"id":"https://openalex.org/keywords/partitioned-survival-model","display_name":"partitioned survival model","score":0.6299999952316284},{"id":"https://openalex.org/keywords/seer-database","display_name":"SEER database","score":0.5009999871253967},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.722000002861023}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.9730533361434937},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8424917459487915},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.7703198194503784},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5448009371757507},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5208650231361389},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5150901675224304},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.47017043828964233},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.46108290553092957}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.8021","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.8021","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.8021","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8560000061988831}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2406890959","https://openalex.org/W2982423776","https://openalex.org/W2995144404","https://openalex.org/W6977562038","https://openalex.org/W2761712406","https://openalex.org/W2947966808","https://openalex.org/W2375156537","https://openalex.org/W2727698853","https://openalex.org/W2332257146","https://openalex.org/W2775974766"],"abstract_inverted_index":{"8021":[0],"Background:":[1],"In":[2],"ASPIRE,":[3],"KRd":[4,39,245,271,290,305],"achieved":[5],"superior":[6],"progression":[7],"free":[8],"survival":[9,54],"(PFS)":[10],"(HR":[11],"=":[12,15],"0.69;":[13],"p":[14],"0.0001)":[16],"and":[17,51,61,75,90,98,146,179,191,209,242,260,318,341],"improved":[18],"quality":[19],"of":[20,38,106,204,214,287,298,315,327],"life":[21,255,258,263,310],"(QoL)":[22],"(p":[23],"<":[24],"0.001)":[25],"over":[26,100,267,312],"Rd":[27,41,218,227,288,322,334],"in":[28,135,152,160,221,229,274],"patients":[29,340],"(pts)":[30],"with":[31,47,70,80,94,131,295],"R/RMM.":[32],"We":[33],"assessed":[34,201],"the":[35,58,101,149,202,268,285,313],"cost-effectiveness":[36],"(CE)":[37],"vs":[40],"from":[42,49,57,144],"a":[43,81,324],"US":[44],"payer":[45],"perspective":[46],"data":[48,56,121,190],"ASPIRE":[50,123,137,189],"long-term":[52],"overall":[53],"(OS)":[55],"Surveillance,":[59],"Epidemiology,":[60],"End":[62],"Results":[63],"Program":[64],"(SEER).":[65],"Methods:":[66],"A":[67,224,234],"partitioned-survival":[68],"model":[69,302],"progression-free":[71],"(PF),":[72],"post-progression":[73],"(PP)":[74],"death":[76],"states":[77],"was":[78,92,186,193,232,238,246,282],"built":[79],"30":[82],"year":[83,264],"horizon.":[84,103,270],"Treatment":[85],"(Tx)":[86],"effect":[87],"for":[88,148,173],"PFS":[89],"OS":[91,108,113],"estimated":[93,117],"parametric":[95],"regression":[96],"models":[97],"applied":[99,239],"time":[102],"Since":[104],"60%":[105],"pre-specified":[107],"events":[109,129],"were":[110,116,139,142,158,182],"observed,":[111],"post-trial":[112],"transition":[114],"probabilities":[115],"by":[118],"matching":[119],"SEER":[120],"to":[122,164,207,240,250,333,339],"pts.":[124],"Grade":[125],"\u2265":[126],"3":[127],"adverse":[128],"(AEs)":[130],">":[132],"2%":[133],"incidence":[134],"any":[136],"arm":[138],"included.":[140],"Utilities":[141],"derived":[143,187],"literature":[145],"adjusted":[147],"relative":[150],"improvement":[151],"QoL":[153],"increase":[154],"observed":[155],"when":[156,331],"pts":[157],"PF":[159,254],"ASPIRE.":[161],"Costs":[162],"related":[163],"drug":[165,219],"(WAC":[166],"prices)":[167],"as":[168,170],"well":[169],"wastage":[171],"(30%":[172],"carfilzomib),":[174],"administration,":[175],"monitoring,":[176],"AE":[177],"management,":[178],"subsequent":[180],"Tx":[181,184],"considered.":[183],"duration":[185],"fitting":[188],"carfilzomib":[192,206,330],"dosed":[194],"upto":[195],"18":[196],"cycles.":[197],"The":[198,301],"base":[199],"case":[200],"CE":[203,279],"adding":[205],"Rd,":[208,251],"considered":[210],"only":[211],"additional":[212,276,293,309],"costs":[213,220,228,241,294],"carfilzomib,":[215],"i.e.":[216],"neglecting":[217],"both":[222,230],"arms.":[223],"scenario":[225],"including":[226],"arms":[231],"conducted.":[233],"3%":[235],"discount":[236],"rate":[237],"outcomes.":[243],"Results:":[244],"more":[247],"effective":[248],"compared":[249],"providing":[252],"1.134":[253],"year,":[256,259],"1.927":[257],"1.616":[261],"quality-adjusted":[262],"(QALY)":[265],"gains":[266],"modelled":[269],"incurred":[272,291],"$123,524":[273],"total":[275],"costs.":[277],"Incremental":[278],"ratio":[280],"(ICER)":[281],"76,416$/QALY.":[283],"With":[284],"inclusion":[286],"costs,":[289],"$179,863":[292],"an":[296],"ICER":[297],"111,270$/QALY.":[299],"Conclusions:":[300],"predicts":[303],"that":[304],"delivers":[306,335],"nearly":[307],"2":[308],"year\u2019s":[311],"standard":[314],"care":[316],"(Rd),":[317],"is":[319],"cost-effective":[320],"vs.":[321],"at":[323],"willingness-to-pay":[325],"threshold":[326],"120,000$/QALY.":[328],"Therefore,":[329],"added":[332],"considerable":[336],"incremental":[337],"value":[338],"payers.":[342]},"counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-18T09:31:52.927876","created_date":"2018-09-27T00:00:00"}